AI is becoming ubiquitous in biopharma, but no company can unlock its full potential alone. As the industry shifts from "tell me" to "show me," the pressure is on to move beyond the hype and use AI to fundamentally reshape how we discover and deliver medicines. Integrating AI "end-to-end" transforms the entire R&D journey—identifying targets, turbo-charging drug design, and optimizing clinical trials and manufacturing. However, real impact requires bringing together diverse expertise: biology, chemistry, clinical insight, and high-performance computing. Strategic partnerships with AI innovators are no longer optional; they are essential to scale discovery and streamline data management. This session explores the opportunities and challenges in building collaborations that move AI from a mere promise to tangible proof of impact across drug discovery and development.